NASDAQ: CARL · Industrial Applications and Services · 5 alerts · CIK 1794546
Share price
$17.35Close, Nov 16
Market cap
$475M
Shares outstanding
27.4MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Carlsmed, Inc. filings on SEC EDGAR ↗
Carlsmed, Inc. reported revenue of $56.6 million for the nine months ended September 30, 2026, a significant increase from $35.3 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $31.5 million for the first nine months of 2026 as operating expenses, particularly in sales, marketing, and general administration, increased substantially.
Carlsmed reported Q3 2026 revenue of $21.6 million, a 65% increase year-over-year, driven by a 60% expansion of its surgeon user base. The company raised its full-year 2026 revenue guidance to $78-$80 million and highlighted new CMS inpatient reimbursement for its aprevo lumbar spine fusion procedure.
Term
Q3 2026
“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year.”
Mike Cordonnier, Chairman and CEO
“We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”
Carlsmed COO Jeffrey Bertolini Sells $11.3K of Stock
Jeffrey Bertolini, COO, sold 747 shares of Carlsmed, Inc. at $15.15 a share, worth $11.3K in total on Nov 3, 2026. Shares held after the trade: 22,489 (-3.2%).